Israeli Companies Announce Medical Breakthroughs and Investments
Israeli firm Raziel Therapeutics has announced successful Phase III clinical trials in China for its injectable drug designed to dissolve double chin fat. The drug targets and breaks down fat cells, preventing future accumulation. The trial, involving 480 participants, showed significant improvements in chin appearance, with results lasting up to 84 days post-treatment. Raziel plans to seek marketing approval in China by the end of 2026, in partnership with Fosun Pharma. The company is also exploring applications for localized fat reduction in other body areas.
In a separate development, Medtronic, a major medical device company, is investing up to $80 million in Israeli startup Pi-Cardia. Pi-Cardia has developed a method for controlled cutting of heart valve leaflets to facilitate the implantation of new valves via catheterization. This strategic agreement includes an option for Medtronic to acquire Pi-Cardia for $210 million, with additional performance-based payments. Pi-Cardia was founded by Erez Golan and Ilan Kalka, who previously founded Topspin, a company that developed a miniature intravascular MRI device.
Meanwhile, SuperWave, traded on the Tel Aviv Stock Exchange, has published trial results in Aesthetic Surgery journal demonstrating its muscle-toning device's effectiveness. The study showed a significant functional improvement in muscle endurance and strength in participants undergoing the treatment, with most benefits sustained a month later. The device is particularly aimed at individuals undergoing GLP-1 weight loss treatments who risk muscle mass loss. SuperWave reported $30 million in revenue for the second quarter of 2026, a 43% increase year-over-year.
Amai Proteins has received marketing approval in Israel for its "Sweetlin" protein, a sweetener developed using computational biology. This approval follows earlier authorizations in the US and Singapore. Sweetlin, suitable for use in dairy drinks, juices, sauces, and chocolate, offers significant sugar reduction without a noticeable aftertaste, though it does not contribute to food texture. The company is led by CEO Dr. Amir Gutman.
Finally, Femi, a private healthcare services company, has launched a home-based ADHD diagnosis service aiming for completion within 72 hours. This service addresses the lengthy diagnostic process typically exceeding six months in Israel's public and private healthcare systems. Femi aims to provide timely diagnoses for children, adolescents, and students needing accommodations. The company estimates that 20,000-25,000 individuals are diagnosed with ADHD in Israel annually.
